Hypoacetate 667 Tablet contains Calcium Acetate 667 mg as its active ingredient and is primarily indicated for the management of hyperphosphatemia in patients with chronic kidney disease (CKD) undergoing dialysis. Calcium Acetate acts as a phosphate binder by binding dietary phosphate in the gastrointestinal tract, thereby reducing phosphate absorption and serum phosphate levels. This mechanism helps prevent complications associated with elevated phosphate, such as secondary hyperparathyroidism and renal osteodystrophy. Hypoacetate 667 is typically administered orally with meals to maximize phosphate binding efficacy. Dosage should be individualized based on serum phosphate levels and patient response, with regular monitoring recommended to avoid hypercalcemia, a potential adverse effect due to calcium overload. Common side effects may include gastrointestinal disturbances such as nausea, vomiting, constipation, or diarrhea. Caution is advised in patients with hypercalcemia, vascular calcification, or those receiving concomitant calcium-containing medications. Hypoacetate 667 should be used under strict medical supervision, with periodic assessment of serum calcium, phosphate, and parathyroid hormone levels to ensure therapeutic effectiveness and safety. This medication is an essential component in the comprehensive management of mineral and bone disorder in CKD patients.